喹硫平治疗帕金森病合并精神障碍疗效观察.docVIP

喹硫平治疗帕金森病合并精神障碍疗效观察 　　[摘要] 目的 探讨喹硫平治疗帕金森病（PD）合并精神障碍的疗效及不良反应。方法 收集PD合并精神障碍患者共78例。所有患者均伴有精神行为异常1个月以上，其中以阳性症状为主要表现者42例，以阴性症状为主要表现者36例。78例患者随机分为两组，治疗组40例，对照组38例。治疗组在调整抗帕金森药物的基础上加用喹硫平50～400mg/d，观察8周；对照组仅予以调整抗帕金森药物的治疗。治疗前后以统一帕金森病评定量表（UPDRS）评定运动功能；以阳性症状和阴性症状量表（PANSS）评定精神障碍程度及疗效；以副反应量表（TESS）评定不良反应。结果 两组患者治疗后PANSS评分均比治疗前减少，以治疗组减少程度较大，两组差异有统计学意义（P0.05）；治疗组不良反应少，未出现严重不良反应。结论 喹硫平治疗PD合并精神障碍的疗效肯定，不良反应少，安全性强，值得临床应用和推广。 　　[关键词] 喹硫平；帕金森病；精神障碍 　　[中图分类号] R742.5；R749.1 [文献标识码] B [文章编号] 2095-0616（2014）04-100-03 　　Clinical effect observation of quetiapine in the treatment of Parkinsons disease complicated with mental disorder 　　HUANG De ZOU Junmin LI Gandong 　　Department of Neurology，Maoming Agricultural Settlement Hospital，Gaozhou 525200，China 　　[Abstract] Objective To investigate the efficacy and adverse reactions of quetiapine in the treatment of Parkinsons disease（PD） complicated with mental disorder. Methods 78 patients with Parkinsons disease complicated with mental disorder were included. All of them had psychological and behavioral abnormality for more than one month，including 42 cases with positive symptom and 36 cases with negative symptom. 78 patients were randomly divided into two groups with 40 cases in the treatment group and 38 cases in the control group. The treatment group was given 50～400mg of Quetiapine per day as well as anti-Parkinson drugs and then was observed for 8 weeks while the control group only received anti-Parkinson drugs. Before and after the treatment，the unified parkinsons disease Rating Scale（UPDRS） was adopted for functional assessment，the positive and negative syndrome scale（PANSS） for the evaluation of mental disorder and efficacy and the treatment emergent symptom scale（TESS） for assessing the adverse reactions. Results After the treatment， the PANSS score decreased in both groups with greater drop in the treatment group. There was statistically significant difference in both groups（P0.05）. There were fewer adverse reactions in the treatment